Advertisement


Clifford A. Hudis, MD, FASCO, FACP, on ASCO Guidelines Assistant

2025 ASCO Annual Meeting

Advertisement

Clifford A. Hudis, MD, FASCO, FACP, Chief Executive Officer of ASCO, discusses ASCO Guidelines Assistant, an AI-based collaboration between ASCO and Google Cloud which draws from ASCO’s evidence-based, published clinical practice guidelines, offering clinicians ready access to timely, trustworthy information.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
I want to welcome everybody to the 2025 ASCO Annual Meeting. This is, as always, an exciting time in the year for us, when so much new science gets presented. Today, what I’m really excited about—above and beyond the cutting-edge new knowledge that’s being shared at this meeting—is how we’re going to distribute it to maximize impact for patients everywhere. The growth in information is something that we’re all grappling with. The explosion in publications—papers, that is—and information that could truly benefit patients is, I think, well known. The question is: how do we keep up? Even within ASCO, where we generate trusted, vetted, expert-prepared, peer-reviewed guidelines, it can be a problem just to find the information that a busy clinician needs in their day to make sure they are offering their patients the most up-to-date care possible. So thinking about those two related issues—the exploding basis of knowledge and the challenge of navigating to quick, accurate answers that a clinician can trust—the last year for us at ASCO has been an exciting one. We’ve partnered and collaborated with Google Cloud to create the ASCO Guidelines Assistant. And it is exactly what the name says—it’s really a discovery tool. What’s different about it compared to some other chat experiences that members may have had is that its answers to our questions are limited to the content of our guidelines. For every answer it gives, it automatically provides the relevant citation. If a user clicks on it, it shows them the specific guideline, when it was last updated, and it highlights in yellow the specific text within the guideline that supports the statement. So it addresses the question of trust, it addresses the question of discoverability, and it addresses the question of timeliness. We are really excited to be able to offer that to all of our members simply by logging on to the ASCO member app or going directly to the website at asco.org. GA—the name standing for Guidelines Assistant—is a small but really important step, I think, in our continuing journey to bring optimal, high-quality care to patients everywhere.

Related Videos

Gastrointestinal Cancer

Yelena Y. Janjigian, MD, on Gastric/GEJ Cancer: Immunotherapy Plus FLOT

Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center, presents event-free survival data from the phase III MATTERHORN trial of the PD-L1 inhibitor durvalumab plus FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy) in patients with resectable gastric or gastroesophageal junction (GEJ) cancer (LBA5). 

Prostate Cancer

Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?

Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARANOTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients with metastatic hormone-sensitive prostate cancer (Abstract 5004). 

Leukemia

Nitin Jain, MD, on Front-Line Therapies for CLL: Research Highlights From ASCO 2025

Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual Meeting. 

Lung Cancer

Luis G. Paz-Ares, MD, PhD, on IMforte Trial in Extensive-Stage SCLC

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, presents primary results from the phase III IMforte trial, which evaluated lurbinectedin plus atezolizumab as first-line maintenance treatment in patients with extensive-stage small cell lung cancer (SCLC) (Abstract 8006).

Breast Cancer

Erika Hamilton, MD, on ER-Positive HER2-Negative Advanced Breast Cancer: Vepdegestrant vs Fulvestrant

Erika Hamilton, MD, Director, Breast Cancer Research at Sarah Cannon Research Institute, reviews data from the global, randomized, phase III VERITAC-2 study, which compared vepdegestrant, an oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor degrader, to fulvestrant among patients with ER-positive HER2-negative advanced breast cancer. Vepdegestrant is the first PROTAC to be evaluated in a phase III trial (Abstract LBA1000). 

Advertisement

Advertisement




Advertisement